Zero new cases of leprosy will only be achieved if we interrupt the transmission by diagnosing and treating patients earlier.
There is no easy point-or-care test for leprosy and initial symptoms can be difficult to detect and are after misdiagnosed.
The Novartis Foundation has been working with research partners to develop a leprosy molecular diagnostic test. The hope is that, once this test is developed, leprosy can be diagnosed before significant nerve damage has taken place, and before it is unknowingly transmitted to others.
Our partners involved in the development of this diagnostic tool include École Polytechnique Fédérale de Lausanne and Fiocruz.